Sexual identity gaps in drug use held steady across 17 years in England
England’s repeated psychiatric morbidity surveys show a stubborn social gradient in past-year drug use: adults with a minority sexual identity continued to report higher use than heterosexual adults in 2007, 2014 and 2024. The newest analysis draws on nationally representative household samples and finds that the disparity never closed, despite major changes in public awareness, drug markets and the language used to describe sexual identity over the same period.
Among adults aged 16 years and older in 2024, past-year drug use was reported by 9.1% of heterosexual adults, 18.3% of gay or lesbian adults, 26.8% of bisexual adults and 28.3% of adults identifying another way. Those differences are not small fluctuations around a common average; they point to a persistent excess burden concentrated in sexual minority communities. The pattern fits long-standing evidence that discrimination, concealment, stress and social exclusion shape substance use trajectories over time, rather than simply reflecting individual choice.
Repeated surveys showed the same divide in younger adults
The clearest time trend came from adults aged 16 to 64 years, the group used for direct comparisons across the three survey waves. Sexual minority adults reported past-year drug use at 22.9% in 2007, 27.5% in 2014 and 24.9% in 2024. Heterosexual adults in the same age band reported 10.3%, 9.9% and 11.6% across those same years. The gap remained roughly twofold or more in every survey round, which makes the persistence especially striking.
Adjusted analyses told the same story after accounting for age, sex and area deprivation. The odds of past-year drug use among sexual minority adults were 2.4 times those of heterosexual adults in 2007, rose to 3.2 times in 2014, and remained 2.2 times higher in 2024. Those estimates suggest that structural and psychosocial forces continued to operate across a 17-year span, even as the surveys themselves evolved and the composition of the population shifted.
The widening of the gap between sexual minority and heterosexual women appeared particularly concerning, although the confidence intervals were wide. Even with that uncertainty, the direction of travel matters clinically and socially: women in sexual minority groups may be carrying a disproportionate share of substance-related risk that is not being fully captured in routine public health monitoring.
Minority stress remains a plausible driver
The most plausible interpretation is rooted in minority stress. Repeated exposure to stigma, rejection, harassment and the pressure to monitor or conceal identity can increase psychological distress and, in some people, create conditions where substance use becomes a coping strategy. Drug use is not explained by identity itself; it is shaped by the environments surrounding identity. When exclusion persists, the health consequences tend to persist with it.
Potency and adulteration in illicit drug markets add another layer of concern. A higher prevalence of drug use in sexual minority populations means greater exposure to unpredictable products, overdose risk, dependence and mental health complications. Even when prevalence remains stable, harms can still intensify if the substances being used become more potent or more toxic over time. The survey does not measure those downstream harms, but the public health implication is difficult to ignore.
What the survey design can and cannot show
The evidence comes from the Adult Psychiatric Morbidity Surveys of 2007, 2014 and 2024, with sample sizes of 7,403, 7,546 and 6,912 respectively. These are repeated cross-sectional probability samples of the household population in England, which gives the findings national reach. Weighted analyses and adjustment for age, sex and area deprivation strengthen the inference that the pattern is not an artefact of a single local sample.
Still, cross-sectional surveys cannot establish causality. They can identify persistent inequity with precision, but they cannot prove which specific social mechanism drives any one individual’s drug use. The study also centered on sexual identity rather than gender identity, and the authors call for future surveys to collect gender identity and to be large enough to disaggregate both sexual and gender identities. For a population as heterogeneous as sexual minority communities, that distinction is essential for understanding who is being missed by broad averages.
Routine drug statistics need a sexual identity lens
The policy message is straightforward. If routine drug surveillance continues to report population averages without sexual identity breakdowns, these disparities will remain partly invisible. The survey findings argue for drug prevention, treatment and policy responses that are designed with sexual minority communities in mind, not retrofitted afterward.
Services working in addiction medicine, psychiatry and public health need to account for the social context in which use occurs. Screening, harm reduction and treatment access should be sensitive to discrimination, concealment, housing insecurity, social isolation and prior negative experiences with healthcare. Generic interventions may miss the people at highest risk if they do not acknowledge how identity-linked stressors shape use patterns.
The preprint status of the analysis also matters. It is a strong epidemiologic signal, but it still awaits peer review. Even so, the core result is already clear from the data presented: sexual identity inequalities in past-year drug use have not gone away in England, and they have remained visible across three national survey waves spanning nearly two decades.